Biotech Stocks Healthcare Stocks Life Sciences

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at. For those who don't know what the patent…

ByNick Sundich

09

Oct 2025

Biotech Stocks Healthcare Stocks

Mesoblast (ASX:MSB): Which direction will this rollercoaster of a $3bn biotech company go next?

Biotech company Mesoblast (ASX:MSB) is the ultimate definition of a rollercoaster company. As of October 7, 2025, it is capped at $3.2bn, which makes it the third largest 'biotech' behind…

ByNick Sundich

19

Dec 2024

Blue Chip Stocks Gold Stocks Healthcare Stocks Small Caps Stocks Tech Stocks Technology

Here are 6 of the best performing ASX shares in 2024! Will they maintain the momentum in 2025?

Here are 6 of the best performing ASX shares in 2024! Mesoblast (ASX:MSB) - up 527% How about this for a turnaround? This stock would've found itself in the list…

ByNick Sundich

29

May 2024

News

Will the RBA Cut Interest Rates in 2024 and, if So, Which Stocks Should I Buy?

The Reserve Bank of Australia (RBA) has been a focal point of economic discussions in 2024. With the cash rate at a 12-year high of 4.35%, Australians are eagerly anticipating…

ByUjjwal Maheshwari

24

Jan 2024

Healthcare Stocks

Revascor’s FDA approval sends the Mesoblast rollercoaster upwards

Its been a rollercoaster ride for Mesoblast (ASX:MSB) shareholders, and although its been mostly downwards, the FDA approval of Revascor sent shares in the other direction. Is this a dead…

ByUjjwal Maheshwari

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

Mesoblast (ASX:MSB): Which direction will this rollercoaster of a $3bn biotech company go next?

Here are 6 of the best performing ASX shares in 2024! Will they maintain the momentum in 2025?

Will the RBA Cut Interest Rates in 2024 and, if So, Which Stocks Should I Buy?

Revascor’s FDA approval sends the Mesoblast rollercoaster upwards

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here